Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Accounts Payables: 2023-2025

Historic Accounts Payables for Contineum Therapeutics (CTNM) over the last 2 years, with Sep 2025 value amounting to $786,000.

  • Contineum Therapeutics' Accounts Payables fell 43.74% to $786,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $786,000, marking a year-over-year decrease of 43.74%. This contributed to the annual value of $1.8 million for FY2024, which is 185.20% up from last year.
  • As of Q3 2025, Contineum Therapeutics' Accounts Payables stood at $786,000, which was down 60.72% from $2.0 million recorded in Q2 2025.
  • In the past 5 years, Contineum Therapeutics' Accounts Payables ranged from a high of $3.6 million in Q1 2025 and a low of $570,000 during Q1 2024.
  • Its 3-year average for Accounts Payables is $1.4 million, with a median of $1.1 million in 2024.
  • Examining YoY changes over the last 5 years, Contineum Therapeutics' Accounts Payables showed a top increase of 539.47% in 2025 and a maximum decrease of 43.74% in 2025.
  • Over the past 3 years, Contineum Therapeutics' Accounts Payables (Quarterly) stood at $635,000 in 2023, then surged by 185.20% to $1.8 million in 2024, then tumbled by 43.74% to $786,000 in 2025.
  • Its Accounts Payables was $786,000 in Q3 2025, compared to $2.0 million in Q2 2025 and $3.6 million in Q1 2025.